Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

3/26/25 9:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $RLMD alert in real time by email

CORAL GABLES, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (NASDAQ:RLMD, "Relmada", or "the Company")), a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies, today announced plans to host a conference call and webcast on Thursday, March 27, 2025 at 4:30 PM ET to discuss recent business progress and financial results for the fourth quarter ended December 31, 2024.

Conference Call and Webcast Information:

Date: Thursday, March 27, 2025 at 4:30 PM ET
Participant Dial-in (US): 1-877-407-0792
Participant Dial-in (International): 1-201-689-8263
Conference: 13751458
Webcast Access: Click Here

A replay of the webcast will be available in the Investors section of the Relmada website at https://www.relmada.com/investors/ir-calendar.

About Relmada Therapeutics, Inc.

Relmada Therapeutics is a clinical-stage biotechnology company committed to advancing innovative breakthrough therapies that have the potential to bring meaningful clinical benefits to targeted patient populations.

Lead investigational program, NDV-01, for High-Grade Non-Muscle Invasive Bladder Cancer, is being evaluated in a Phase 2 study. In addition, preparations are underway to advance sepranolone, a Phase 2b-ready investigational program for compulsion-related disorders including Tourette's Syndrome into further studies.

For more information, visit www.relmada.com.

Investor Contact:

Brian Ritchie

LifeSci Advisors

[email protected]

Media Inquiries:

Corporate Communications

[email protected]

Get the next $RLMD alert in real time by email

Recent Analyst Ratings for

$RLMD

Date	Price Target	Rating	Analyst
12/5/2024	$23.00 → $1.00	Outperform → Neutral	Mizuho
9/17/2024	$3.50 → $13.00	Hold → Buy	Jefferies
6/5/2024	$3.00 → $2.00	Neutral → Sell	Goldman
10/14/2022	$81.00 → $8.00	Buy → Neutral	Goldman
10/14/2022	$90.00 → $10.00	Buy → Hold	Truist
10/14/2022		Buy → Neutral	Guggenheim
10/13/2022	$64.00 → $7.00	Outperform → Perform	Oppenheimer
12/20/2021	$50.00 → $42.00	Outperform	SVB Leerink

More analyst ratings

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Chat with this insight

Recent Analyst Ratings for
$RLMD

$RLMD
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

$RLMD
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025

Chat with this insight

Recent Analyst Ratings for $RLMD

$RLMD Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

$RLMD Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Chief Operating Officer Kelly Paul Edward bought $86,060 worth of shares (200,000 units at $0.43), increasing direct ownership by 94% to 412,295 units (SEC Form 4)

Chief Financial Officer Shenouda Maged bought $97,208 worth of shares (200,000 units at $0.49), increasing direct ownership by 226% to 288,335 units (SEC Form 4)

CA and CO Ence Chuck bought $103,330 worth of shares (228,961 units at $0.45), increasing direct ownership by 588% to 267,931 units (SEC Form 4)

Recent Analyst Ratings for
$RLMD

$RLMD
Insider Purchases

$RLMD
Insider Trading